53. シェーグレン症候群 [臨床試験数:234,薬物数:270(DrugBank:85),標的遺伝子数:49,標的パスウェイ数:174

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR18000146232018-02-012018-01-24A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren SyndromeA prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome Sjogren Syndromestem cell group: Intravenous use mesenchymal stem cell ;hydroxychloroquine group:oral use hydroxychloroquine ;Tongji Hospital of Tongji UniversityNULLRecruitingBothstem cell group:20;hydroxychloroquine group:20;China
2EUCTR2014-003140-12-NL21/09/201526/08/2015Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's SyndromeOptimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - LEF-HCQ combination therapy in pSS Sjogren's Syndrome
MedDRA version: 18.0Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 18.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 18.0Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 18.0Level: LLTClassification code 10040765Term: Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Leflunomide Mylan
Product Name: Leflunomide mylan
INN or Proposed INN: LEFLUNOMIDE
Trade Name: Plaquenil
Product Name: Plaquenil
INN or Proposed INN: HYDROXYCHLOROQUINE
UMC UtrechtNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
Netherlands
3NCT01601028July 201129/4/2012Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's SyndromePhase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's SyndromeAutoimmune Diseases;Sjogren's Syndrome;Dry EyeDrug: Hydroxychloroquine;Drug: PlaceboSeoul National University HospitalNULLCompleted19 YearsN/ABoth39Phase 3Korea, Republic of
4JPRN-UMIN0000044772010/11/0101/11/2010Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunk Systemic/cutaneous lupus erythematosusSjogren's syndromeHydroxychloroquine 200 mg will be administrated once daily. If insufficient, dosage can be escalated to 400 mg twice daily, but not exceed 6.5 mg/kg/day.Kanazawa University Graduate School of Medical ScienceNULLComplete: follow-up complete20years-old75years-oldMale and Female10Not appl1cableJapan
5NCT00632866March 200829/2/2008Hydroxychloroquine Versus Placebo in Primary Sjögren's SyndromeRandomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's SyndromePrimary Sjögren's SyndromeDrug: Hydroxychloroquine;Drug: PlaceboAssistance Publique - Hôpitaux de ParisSanofiCompleted18 YearsN/ABoth120Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00873496January 200531/3/2009Effects of Hydroxychloroquine on Oral Complaints of Sjögren PatientsEffects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study.Sjögren's Syndrome;XerostomiaDrug: HydroxychloroquineEge UniversityNULLCompletedN/AN/AFemale30N/ATurkey